Mr. Raj Shah reports

GUIDEAI HEALTH CORP. AND VRAD RENEW DATA EXCLUSIVITY AGREEMENT TO DEVELOP AI MODELS FOR THE DETECTION AND CHARACTERIZATION OF MULTIPLE VASCULAR DISEASES

GuideAI Health Corp. has renewed its data exclusivity agreement with vRad (Virtual Radiologic), which aims to develop artificial intelligence models for the detection and characterization of multiple vascular diseases. The renewed collaboration provides GuideAI with exclusive access to imaging data from more than 2,100 hospitals across the United States, which the company believes to be one of the largest and most diverse real-world imaging data sets of its kind.

Under the renewed partnership, GuideAI retains exclusive rights to develop AI (artificial intelligence) models using deidentified imaging data generated across vRad's national network of more than 2,100 hospitals and health care facilities. GuideAI's technology is currently deployed within the workflow of vRad's approximately 500 radiologists, where it supports the identification of vascular disease at the point of care.

The scale and diversity of vRad's data set provide GuideAI with a durable foundation on which to train and validate its algorithms. Building on its work in peripheral arterial disease, the company intends to expand its platform to the detection and characterization of multiple vascular diseases, with the goal of surfacing disease earlier and supporting more precise, more comprehensive treatment decisions for patients nationwide.

GuideAI Health chief executive officer Raj Shah commented: "Renewing our exclusive data collaboration with vRad is a defining moment for GuideAI. Access to imaging data from more than 2,100 hospitals, combined with the trust of the 500 radiologists who already have access to our technology in their daily workflow, gives us an exceptional foundation to build clinically meaningful AI, furthering our aim of helping clinicians catch disease earlier and improve outcomes for patients."

About GuideAI Health Corp.

GuideAI Health is a health care technology company using artificial intelligence to enable the early detection of vascular disease and support more precise treatment decisions. Its platform analyzes routine CT scans to identify peripheral vascular disease. By surfacing disease earlier, GuideAI aims to improve patient outcomes while helping hospitals and radiology groups deliver more comprehensive vascular care.

We seek Safe Harbor.